Article Details
Retrieved on: 2025-02-25 13:41:23
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses AIM ImmunoTech's Phase 2 clinical trial of Ampligen with durvalumab for late-stage pancreatic cancer, highlighting its biotech potential. Tags like 'Orphan drugs' and 'Cancer immunotherapy' relate through the focus on innovative, targeted cancer therapies.
Article found on: www.stocktitan.net
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here